in vitro News and Research

RSS

In vivo structure of senile plaques in brains of people with Alzheimer's disease

A team of scientists from Britain and the United States believe they may have identified the true in vivo structure of the senile plaques that are characteristically found in the brains of people with Alzheimer's disease.

11 Jun 2010

ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

ViroStatics, srl, an Italian-US biopharmaceutical company today announced the formation of a strategic partnership with Vichem Chemie of Budapest, Hungary to identify, synthesize, screen, and develop the next generation of AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of HIV/AIDS and other chronic diseases.

11 Jun 2010

Idenix initiates IDX320 proof-of-concept study for HCV infection

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.

10 Jun 2010

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, commented today on a recent study in The Journal of Medicine that both raw and cooked ginger reduce pain associated with muscle injury by about 24%, compared with placebo. The study was supported by the McCormick Science Institute.

10 Jun 2010

StemCells' GS2-M cell culture media formulation enhances pluripotency of human ES, iPS cells

StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.

10 Jun 2010

Veiovis, Medtral New Zealand announce new partnership

Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.

10 Jun 2010

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

10 Jun 2010

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, and Bayer Schering Pharma AG, a global leading specialty pharmaceuticals company, announced today the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.

10 Jun 2010

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

In what could lead to a major advance in the treatment of prostate cancer, scientists now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal, explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth.

10 Jun 2010

Bayer receives silver Medical Design Excellence Award for CONTOUR USB blood glucose meter

Bayer's CONTOUR® USB meter, the first blood glucose monitor with unique plug & play diabetes management software, today received a silver Medical Design Excellence Award (MDEA). The MDEA recognizes excellence in medical product design and manufacturing. The independent judges for the prestigious award, sponsored by the specialist journal Medical Device and Diagnostic Industry, acknowledged the great innovative power and particularly user-friendly operation of Bayer's CONTOUR USB meter.

10 Jun 2010

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approval for its SPR-based HPV-DNA chip from the State Food and Drug Administration of China (the "SFDA").

10 Jun 2010

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

QuantRx Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader thyroid testing system.

9 Jun 2010

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Keryx Biopharmaceuticals, Inc. today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL.

7 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

Celera Corporation today announced that it has signed a Declaration of Conformity and applied the CE mark to a real-time PCR (polymerase chain reaction) test for detection of a variant in the KIF6 gene, allowing the test to be marketed in the European Union and other geographic areas that recognize the CE Mark.

7 Jun 2010

in vitro News and Research

In vivo structure of senile plaques in brains of people with Alzheimer's disease

ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

Idenix initiates IDX320 proof-of-concept study for HCV infection

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

StemCells' GS2-M cell culture media formulation enhances pluripotency of human ES, iPS cells

Veiovis, Medtral New Zealand announce new partnership

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Scientists discover how polyphenols present in red wine and green tea inhibit prostate cancer growth

Bayer receives silver Medical Design Excellence Award for CONTOUR USB blood glucose meter

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Pharnext closes €4.8-million Series A funding round

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

CytRx granted U.S. Patent for bafetinib

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News